CommercialPrior AuthMedium impact
08.01.69f, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™) have been updated for commercial insurance plans. This affects prior authorization requirements and coverage criteria for these cancer immunotherapy drugs.
Action Required
By August 25, 2025: Billing team must review updated medical necessity criteria for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™) prior authorization requests. Update prior auth submission forms and ensure providers document all required medical necessity criteria. Claims may be denied if new criteria are not met.